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A B S T R A C T
Heart failure (HF) is a dominant cause of morbidity and mortality in the developed world, with available pharmacotherapies limited by high rates of residual
mortality and a failure to directly target the changes in cell state that drive adverse cardiac remodeling. Pathologic cardiac remodeling is driven by stress-activated
cardiac signaling cascades that converge on deﬁned components of the chromatin regulatory apparatus in the nucleus, triggering broad shifts in transcription and cell
state. Thus, studies focusing on how cytosolic signaling pathways couple to the nuclear gene control machinery has been an area of therapeutic interest in HF. In this
review, we discuss current concepts pertaining to the role of chromatin regulators in HF pathogenesis, with a focus on speciﬁc proteins and RNA-containing
macromolecular complexes that have shown promise as druggable targets in the experimental setting.
Heart failure (HF) is a global epidemic and represents a leading
cause of morbidity and mortality in the developed world [1–5]. Life-
time risk for developing HF has been estimated to be as high as 20%,
with the prevalence projected to increase over the next two decades.
This increased prevalence is not only the result of our success in
treating patients with myocardial infarction (MI) and our growing
ability to stabilize acute cardiovascular events [5–7], but is also caused
by an aging populace and rising rates of comorbidities including obe-
sity, hypertension, and diabetes [8,9]. Currently available therapeutic
modalities to treat HF, which mostly focus on blockade of circulating
neurohormone activity, are inadequate as reﬂected by high rates of
residual mortality in patients adhering to guideline directed medical
therapy. Furthermore, neurohormonal antagonism does not directly
alter root-cause defects in cardiac tissue and often only slows disease
progression rather than preventing or reversing it. The fact that nearly
half of those who develop HF die within 5 years of diagnosis highlights
the urgent need to identify completely new axes of disease pathogenesis
and leverage this knowledge toward the development of novel therapies
[4,10].
Abnormalities in cardiac gene regulation represent a new axis of HF
pathogenesis and emerging research implicates the transcriptional ap-
paratus as a novel therapeutic target. The last decades have seen major
advances in our understanding of how stress- or injury-induced cardiac
signaling cascades converge on the nucleus to trigger global shifts in
gene expression that contribute to adverse cardiac remodeling and
impaired cardiac function [11,12]. Importantly, a host of studies using
genetic gain- and loss-of-function approaches have highlighted the
functions of a set of core transcription factors (TFs), such as NFAT,
MEF2, NF-κB, GATA4 and C-MYC, in sustaining and amplifying the
gene regulatory networks (GRNs) critical for pathological cardiac re-
modeling in vivo [12]. These stress-induced gene programs drive pa-
thologic processes including cardiomyocyte (CM) hypertrophy, altered
substrate metabolism and energetics, myoﬁbroblast (myoFB) activa-
tion, and innate inﬂammatory responses, all of which collectively fuel a
vicious cycle that culminates in cardiac structural changes and pro-
gressive contractile dysfunction. Current pharmacological therapies
generally target very proximal steps in stress-dependent cardiac sig-
naling (e.g., antagonists of the ß1 adrenergic receptor and blockade of
renin-angiotensin signaling) [5,13]. These stress-induced pathways ul-
timately converge on TFs and the chromatin regulatory apparatus in the
nucleus, which transduce these broad upstream signals into changes in
gene expression and cell identity. For these reasons, the study of how
cytosolic signaling pathways couple to the nuclear gene control ma-
chinery has been an area of intense scientiﬁc and therapeutic interest.
In this review, we provide an overview of current concepts pertaining to
the role of chromatin regulators in HF, with a particular focus on pro-
tein and RNA-containing macromolecular complexes that have been
shown to have translational potential in proof-of-concept experimental
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studies.
1. Epigenetic regulation of gene expression
How cells within the human body, all of which share the same DNA
sequence, diﬀerentiate into the myriad of distinct cell types with highly
specialized functions remains one of the most fascinating questions in
biology. This remarkable process is achieved, in a large part, through
epigenetic control of gene expression, which orchestrates strict spatio-
temporal control of cell state-deﬁning gene programs. The term epi-
genetics [14] refers to the layer of chemical modiﬁcations that exists
above (‘epi’) the DNA sequence (‘genetic’) and allows the genome to
function distinctively in diﬀerent cell types. The epigenome comprises
all of the processes that dynamically shape chromatin to modulate cell-
state speciﬁc gene expression, including methylation of DNA and post-
translational modiﬁcation of histone tails [15, 16]. Active transcription
of genes is inﬂuenced by the activity of DNA regulatory elements called
enhancers, deﬁned as cis-acting DNA modules that are needed to acti-
vate and sustain transcription at their target promoters. Enhancer ac-
tivity is dynamic and can be restricted to a particular tissue or cell type,
speciﬁc time point, or a precise physiologic, pathologic, or environ-
mental condition [17]. Collectively, these features allow for the tem-
poral, spatial, and quantitative control of gene expression. Enhancers
are the key information processing units that regulate the expression of
cell-state deﬁning gene regulatory networks (GRNs) and are char-
acterized by enrichment of regulatory transcription factor (TF) binding
sites, active chromatin marks (e.g., acetylation of histone H3 lysine 27,
H3K27ac), and binding of co-activator proteins (e.g., BRD4, MED1)
[18]. Cell state is dictated and maintained by the binding of core TFs to
their cognate DNA motifs on target enhancers, which ultimately results
in remodeling of regional chromatin and assembly of the transcriptional
machinery. Several studies have deﬁned how changes in the enhancer
landscape dictates cardiac cell fate speciﬁcation and diﬀerentiation
[19–21]. In an analogous manner, the activation of pathologic tran-
scriptional programs in the stressed heart (e.g., transformation of a
healthy CM into one that is hypertrophic and dysfunctional) is triggered
by pathologic rewiring of the enhancer and transcriptional landscape
[22,23]. In mouse models of pressure overload cardiac hypertrophy,
chromatin immunoprecipitation coupled with massively parallel se-
quencing (ChIP-seq) has been used to map global deposition of several
histone modiﬁcations associated with the activation of a deﬁned epi-
genomic landscape [24]. In particular, the regulation of histone me-
thylation has been shown to play a key role in the maintenance of
cardiac homeostasis and hypertrophy [24–26]. Recently, the laboratory
of Gianluigi Condorelli has characterized the dual function of the his-
tone methyl-transferase G9a in maintaining correct gene expression
programs in normal CMs as well as in driving the gene expression
changes underlying cardiac hypertrophy [27]. G9a exerts this double
function by its ability to repress, via dimethylation of lysine 9 at histone
3 (H3K9me2), diﬀerent sets of genes depending upon the functional
status of the heart. Interestingly, G9a interacts with MEF2C in CMs,
suggesting that broadly expressed histone methyltransferase might
achieve cell- and locus-speciﬁc activity by interacting with cardiac TFs
[27].
Previous studies have highlighted the dynamic interplay between
histone modiﬁcation and CpG site methylation (mCpG) during cardiac
development and CM maturation. Interestingly, mCpG of coding and
cis-regulatory regions is remarkably stable in the setting of HF [28].
While bisulﬁte sequencing can resolve DNA methylation patterns at the
single nucleotide level, it does not discriminate between 5-methylcy-
tosine (5mC) and 5-hydroxymethylcytosine (5hmC) [29]. Recent evi-
dence suggests that the dynamic modulation of hydroxymethylation at
gene bodies is indeed an epigenetic feature that accompanies patho-
logic transcriptional changes in CMs during hypertrophy [30]. Genome-
wide distribution of 5hmC positively correlates with gene expression
and, following pathological hypertrophy, the 5hmC landscape of CMs is
shifted toward a neonatal-like pattern. 5hmC also seems to deﬁne a
small subset of enhancer regions that dynamically respond to pro-hy-
pertrophic cardiac stress [30]. 5hmC at these enhancer regions corre-
lates with gene expression pattern following cardiac hypertrophy,
suggesting the possibility that this subset of hydroxymethylated cis-
regulatory elements may play a role in sustaining the pathological re-
sponse in CMs. Mechanistically, depletion of 5hmC via downregulation
of Tet methylcytosine dioxygenase 2 (Tet2) aﬀects enrichment of the
active chromatin mark H3K27ac within enhancer regions, with con-
sequent decreased expression of local genes [30]. Recent studies have
also shown that DNA hydroxymethylation is positively correlated with
enhancer activity and chromatin accessibility, and is enriched at the
boundaries of low methylated regions (LMRs) [31]. Importantly, LMRs
with enhancer signatures in CMs are enriched for single nucleotide
polymorphisms (SNPs) linked to coronary heart disease and cardiac
arrhythmias [28]. The pathologic relevance of cardiac cis-acting reg-
ulatory elements is further supported by the observation that cardiac
disease-associated SNPs are enriched in heart-speciﬁc super-enhancers
(SEs), regions of the mammalian genome comprising of multiple en-
hancer clusters that are disproportionately enriched with regulatory TF
binding sites, active chromatin marks (e.g., H3K27ac), and coactivator
protein binding [32,33]. These data support the contention that aber-
rant enhancer-mediated signaling plays a critical role in pathogenesis of
human heart disease.
2. Interdicting signaling from enhancers to RNA Pol II-dependent
transcription as a therapeutic strategy for HF
In response to cardiac stress, a deﬁned set of coordinately activated
TFs bind speciﬁc enhancers in a combinatorial manner. These en-
hancer-bound TFs then recruit diverse cofactors that alter local chro-
matin structure and/or signal to the transcription machinery. Two
major classes of cofactors are those that mobilize the nucleosomes (e.g.
the ATP-dependent chromatin remodeling complexes) and those that
add or remove post-translational modiﬁcations (PTMs) to histone pro-
teins. Of the PTMs, reversible acetylation of histone tail lysine residues
has been the most studied in the context of HF pathogenesis [16,34,35].
Dynamic lysine acetylation is coordinately regulated by histone acet-
yltransferases (HATs) and histone deacetylases (HDACs), also known as
epigenetic “writers” and “erasers”, respectively. These marks are re-
cognized and “read” by proteins that speciﬁcally bind these post-
translational marks. Emerging studies have highlighted the importance
of epigenetic “readers” as important new players in cardiac biology
[16]. These proteins harbor recognition motifs for histone modiﬁca-
tions and also contain domains that scaﬀold the formation of protein
and RNA complexes that mediate downstream transcriptional signaling.
Given the known importance of lysine acetylation in cardiac
biology, a class of epigenetic readers that contain an evolutionary
conserved acetyl-lysine recognition module, or bromodomain (BD),
have drawn particular attention [36,37]. Of these BD-containing reader
proteins, the BET (Bromodomain and Extra-Terminal) family, which
comprise the ubiquitously expressed BRD2, BRD3, BRD4 and testis-
speciﬁc BRDT, has become the subject of intense study given their role
in a variety of cancers and the advent of potent and speciﬁc small
molecule inhibitors against this family [38]. BET proteins are char-
acterized by two tandem N-terminal BDs which are each 110 amino
acids in length [36,37]. These BDs are comprised of four alpha-helices
(Z, A, B, C) and two α-helix-connecting loops (ZA, BC) that provide a
deep hydrophobic pocket for the speciﬁc recognition of acetylated ly-
sine. Of the BET family, BRD4 is the most extensively characterized
given its known role in transcriptional elongation [39,40] and its active
development as a drug target in cancer. BRD4 was originally identiﬁed
as a mitotic chromosome-binding protein that binds acetylated chro-
matin throughout the cell cycle, thus providing “epigenetic memory”
for post-mitotic transcription [41]. BRD4 is localized genome-wide to
both actively transcribed promoters and enhancers, with a
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disproportionate enrichment at SEs [32,42–46]. A direct role of BRD4
in co-activating transcription is evidenced by its ability to associate
with and allosterically activate CDK9, the core kinase in the positive
transcription elongation factor b (P-TEFb) complex [39,40]. P-TEFb is a
critical eﬀector of Pol II transcriptional elongation via its ability to
phosphorylate and inhibit pausing factors such as the DSIF/NELF
complex as well as its ability to phosphorylate key serine residues on C-
terminal heptapeptide repeats of Pol II [47].
Important roles for BRD4 have recently been described in a host of
cell state transitions, including oncogenesis, where BRD4's function is
associated with epithelial-to-mesenchymal transition (EMT), stem cell-
like conversion, and other broad transcriptional rewiring events that
characterize tumor evolution [44,48–53]. Murine loss-of-function al-
leles for Brd2 and Brd4 in the germline demonstrate critical develop-
mental roles for these proteins with homozygous mutant animals de-
monstrating early embryonic lethality [54,55]. The recent development
of potent, speciﬁc, and reversible BET bromodomain inhibitors, such as
the ﬁrst-in-class tri-azolo-thienodiazepine small-molecule JQ1, has
signiﬁcantly accelerated the therapeutic interest in the BET family
[52,56]. JQ1 binds the acetyl-lysine binding pocket of BRD2, 3, and 4
with exquisite shape complementarity, high speciﬁcity, and nanomolar
aﬃnity, competitively displacing BET proteins from their endogenous
acetylated interaction partners [52,56]. Pharmacological inhibition of
BET proteins with JQ1 is therefore a reversible and dose-titratable tool
for understanding the gene regulatory function of BRD4 as molecular
ampliﬁer of enhancer-to-promoter signaling. Importantly, drug deri-
vatives of the tool compound JQ1 are now progressing in early phase
cancer trials, providing a runway for considering BET inhibition in
other disease settings [57]. Mice harboring conditionally targeted Brd4
alleles have recently been developed, allowing for the study of allele-
speciﬁc and cell-restricted gene deletion in vivo [58]. While JQ1 binds
all BET proteins and widely distributes to many tissues in vivo, it should
be emphasized that these tool compounds allow functional probing of
BET proteins in a manner that is wholly diﬀerent from that which can
be achieved by gene deletion/knockdown or bulk protein depletion (as
occurs with heterobifunctional molecules that target BET protein de-
gradation by bringing them into proximity with cellular E3 ubiquitin
ligases) [59]. Importantly, pharmacological inhibition of BET proteins
by pulsatile exposure of the small molecule JQ1 is reversible and
therefore may overcome the potential toxicity associated with Brd4
gene silencing [60].
Two independent and contemporaneous publications from our
groups were the ﬁrst to establish proof of principle that BET reader
proteins are essential co-activators of stress-dependent gene expression
programs during HF pathogenesis [42,61] (for review, see Haldar and
McKinsey 2014 [62]). BET inhibition using either JQ1 or siRNA-
mediated Brd4 knockdown in isolated neonatal rat ventricular myo-
cytes (NRVM) inhibited hallmark features of agonist-induced hyper-
trophy and suppressed stress-mediated gene induction, supporting a
cell-autonomous role of BRD4 in controlling CM cell state during pa-
thological stimulation [42]. To provide human relevance, we subse-
quently demonstrated that JQ1 could suppress endothelin-1 induced
hypertrophy and global stress-gene transactivation in cultured human
iPSC-derived CMs [63]. Importantly, early administration of JQ1 in the
murine transverse aortic constriction (TAC) model of LV pressure
overload potently prevented LV systolic dysfunction, adverse cardiac
remodeling, and cardiomyocyte hypertrophy/ﬁbrosis [42]. In line with
its active chromatin-binding activity, BRD4 ChIP-seq in adult mouse
heart tissue demonstrated that BRD4 enriched at active cardiac en-
hancers and promoters. During TAC-mediated stress, Pol II ChIP-seq
revealed widespread pause-release of Pol II at stress activated genes, a
mechanism attenuated by JQ1 [42]. These data are consistent with the
ability of enhancer-bound BRD4 to interact with the P-TEFb complex
and promote productive Pol II elongation at stress activated genes. In
addition, these ﬁndings corroborate previous work from the laboratory
of Michael Schneider demonstrating that P-TEFb inhibition attenuates
cardiomyocyte hypertrophy in vitro, while transgenic overexpression of
cyclin-T1 (the key regulatory cyclin in the P-TEFb complex) in murine
cardiomyocytes in vivo is suﬃcient to drive pathological cardiac re-
modeling [64]. Together, these ﬁndings support a model in which
stress-activated signaling pathways deploy a deﬁned set of DNA-
binding transcription factors, which then bind speciﬁc enhancer ele-
ments in the stressed myocardium. In turn, BRD4 is recruited to these
enhancer elements, possibly via interactions with acetylated histones
and acetylated transcription factors, where it scaﬀolds transcription
complexes such as CDK9/P-TEFb and triggers pause-release of genes
that have actively poised Pol II at the transcription start site and are
primed for activation [42]. Along this line, recent work in NRVMs has
shown that during agonist mediated stress, BRD4 bound at basal en-
hancers robustly redistributes genome-wide, and becomes asymme-
trically reallocated to a deﬁned set of cardiomyocyte SEs [65]. Im-
portantly, activity of these SEs and their target genes appear to be
preferentially sensitive to local depletion of BRD4 via small molecule
BET inhibition. Furthermore, the gain vs. loss of BRD4 at enhancers
tends to correlate with concordant changes in transcriptional activity at
the respective target genes, suggesting that reallocation of rate-limiting
quantities of BRD4 directly aﬀects gene transactivation. These ﬁndings
are consistent with previous work in cultured endothelial cells during
innate-inﬂammatory activation [46]. In addition to the BRD4/PTEFb
complex, recent studies have also demonstrated that the general tran-
scription factor TFIIB may also play a role in aberrant cardiac gene
regulation during HF pathogenesis, raising the possibility that stress-
dependent regulation of Pol II initiation at a subset of transcription start
sites may also promote adverse cardiac remodeling [66,67].
While these index studies provided the initial insights into the role
of BET protein function in the heart, they relied on early administration
of JQ1 in the prevention of adverse cardiac remodeling and HF pa-
thogenesis. More recently, our group has provided proof of principle for
the therapeutic eﬃcacy of BET inhibition in both the murine pressure
overload and myocardial infarction (MI) models [63]. In the setting of
prolonged pressure overload or a large anterior wall MI, late adminis-
tration of JQ1 was able to treat pre-established HF, attenuating multiple
hallmark features of HF progression in vivo, including LV dysfunction,
LV cavity dilation, cardiomegaly, CM hypertrophy and left ventricle
(LV) ﬁbrosis [63]. Using RNA-seq from whole LV tissue across both the
murine TAC and MI treatment models, we deﬁned a shared set of JQ1-
suppressed genes that represent a common program mediating the
observed therapeutic eﬀects. This common gene signature was strongly
enriched for transcripts involved in pro-ﬁbrotic and innate in-
ﬂammatory processes, with representation of genes that were expressed
in several cell types that populate the stressed myocardium. Gene set
enrichment and ingenuity pathway analyses revealed that JQ1 had a
strong preference for suppressing TGFβ- and NFκΒ-driven transcrip-
tional programs [63]. We found that the eﬀect of JQ1 on diﬀerential
gene expression was much more prominent in the stressed heart than in
the baseline state (i.e. sham-treated), in line with our observation that
JQ1 does not profoundly alter baseline cardiac structure or function at
the doses used in our study. This is consistent with the observation that
stress-dependent gene transactivation requires massive ﬂux of BRD4 to
new SE loci, an event likely to be preferentially sensitive to JQ1
[42,46]. Consistent with the lack of a striking eﬀect on the unstressed
heart, JQ1 treatment at the same doses used in our disease models did
not attenuate exercise-induced cardiac growth in mice, a remodeling
process that does not feature robust activation of ﬁbrosis and in-
ﬂammation [63,68,69]. These observations are consistent with a strong
predilection for inhibiting pro-ﬁbrotic and pro-inﬂammatory cell states
during cardiac stress/injury.
While it is clear that JQ1 exerts potent on-target bioactivity in the
heart and strongly attenuates TGFβ- and NFκΒ-dependent transcrip-
tional programs, the precise identity of cell-types that mediate these
therapeutic eﬀects remains a major unanswered question with im-
portant therapeutic implications. Pro-ﬁbrotic and inﬂammatory gene
M. Alexanian, et al. Journal of Molecular and Cellular Cardiology 130 (2019) 197–204
199
transactivation can emanate from multiple cell types in the adult heart.
As our initial transcriptional analyses were performed on whole heart
tissue, further dissections of cell-intrinsic eﬀects are an important area
of ongoing investigation. We postulate that the therapeutic eﬃcacy of
JQ1 in these models may be via eﬀects on several cell types including
cardiomyocytes, ﬁbroblasts, endothelial cells, and immune cell subsets.
The bulk left ventricular (LV) tissue transcriptomic analyses indicate
that the activated cardiac myoFBs, a key player in wound healing re-
sponses, may serve as a particularly important therapeutic target of BET
inhibitors in vivo [63]. During cardiac stress, resident cardiac ﬁbro-
blasts transition to the activated myoFB cell state, a process that fea-
tures massive transcriptional rewiring allowing the capacity to pro-
liferate, migrate, secrete cytokines, elaborate extracellular matrix,
contract, and recruit immune cells [70]. Similar to observations in
hepatic stellate cells [71], our data suggest that the cell state transition
from a resident/quiescent cardiac ﬁbroblast to an activated myoFB is
highly sensitive to BET inhibition. Finally, we note that there are nu-
merous other co-regulatory molecules that signal from enhancers to the
transcription machinery, raising the possibility that other proteins may
also serve as novel epigenetic targets in HF.
3. lncRNAs: gene regulatory switches that may be therapeutically
manipulated in HF
In addition to proteins, several species of non-coding RNAs have
been shown to play critical roles in chromatin regulation and broad
control of gene expression programs. In this section, we turn attention
to a subset of long noncoding RNAs (lncRNAs) that have emerged as
potentially druggable epigenetic targets in preclinical models of HF.
The mammalian genome is predominantly composed of non-protein
coding sequence, raising the possibility for diverse regulatory functions
of these regions. Deep RNA-sequencing approaches have revealed that
the majority of the non-coding genome is actively transcribed, gen-
erating thousands of non-coding RNAs (ncRNAs) [72–75]. While GRN
activity has been long known to be controlled by TF proteins binding to
their cognate DNA regulatory elements, emerging evidence strongly
supports a similarly critical role for networks of ncRNAs [76,77]. The
best characterized ncRNAs are microRNAs (miRNAs), small single-
stranded ribonucleotides that lead to post-transcriptional silencing by
targeting messenger RNAs for degradation or via translational sup-
pression. Deep genome-wide transcriptomic proﬁling has identiﬁed
other functional classes of transcripts with potentially important reg-
ulatory functions. Long non-coding RNAs (lncRNAs) are operationally
deﬁned as ncRNAs that are longer than 200 nucleotides in length and
exhibit minimal protein coding potential. Currently, the best char-
acterized lncRNAs are processed transcripts that are Pol II transcribed,
multi-exonic, alternatively spliced, and poly-adenylated [78]. While
lncRNAs are typically expressed at a lower level than mRNAs, they
often feature much greater tissue and cell-type speciﬁcity [19,73].
LncRNAs have been shown to regulate diverse biological processes and
are emerging as critical regulators of nearly every aspect of GRN ac-
tivity, including transcriptional control, post-transcriptional processing,
and chromatin remodeling [79]. LncRNAs are unique in their ability to
spatially amplify regulatory information encoded by their underlying
DNA where they can act in both cis and trans. Recently, lncRNAs have
been shown to ﬁne-tune GRNs controlling cardiac lineage speciﬁcation
[19,80,81]. Progress in transcription sequencing technologies have re-
vealed that many functional enhancers are themselves transcription
units that generate ncRNAs [18,82,83]. These exist as two distinct
classes: bidirectional non-poly-adenylated transcripts (enhancer RNAs
or eRNAs); and unidirectional, multi-exonic, spliced, poly-adenylated
processed transcripts (enhancer-associated lncRNAs or elncRNAs).
elncRNAs are important for concentrating TFs to speciﬁc DNA regions
and modifying the local chromatin environment and have emerged as
potential regulators of nuclear three-dimensional topologies [84–86].
Notably, elncRNAs expression is more cell and tissue speciﬁc than
ncRNAs transcribed from non-enhancer regions [19]. Furthermore, SEs
tend to produce more eRNAs than typical enhancers [18,84,87] with
several lncRNAs associated with SEs now emerging as important
modulators of cell fate determination and maintenance of cell identity
in the heart [88,89].
4. Targeting lncRNAs in HF
Mhrt, the ﬁrst lncRNA implicated in pathological hypertrophy, is
located in the intergenic region between Myh6 and Myh7 in mice, and
transcribed in an antisense orientation to Myh7 [90]. In the setting of
pressure overload, Mhrt expression is reduced, an event which appears
to be permissive for adverse cardiac remodeling. Transgenic over-
expression of Mhrt in mice using a cardiomyocyte-speciﬁc promoter is
suﬃcient to protect the heart from stress-induced cardiomyocyte hy-
pertrophy and HF progression. Mechanistic studies demonstrate that
Mhrt antagonizes the activity of BRG1, a chromatin remodeling factor
previously implicated in the control of pathological cardiovascular
GRNs.Mhrt acts as a molecular decoy, binding to the helicase domain of
BRG1 and titrating it away from its DNA targets, thus suppressing ex-
pression of pathological gene programs. Importantly, the human MHRT
ortholog is depleted in failing human hearts, suggesting a conserved
regulatory role of potential translational signiﬁcance.
In 2016, two other lncRNAs named Chast and Chaer were discovered
upon screening for CM-enriched lncRNA species diﬀerentially ex-
pressed with cardiac stress [91,92]. Like Mhrt, both of these lncRNAs
have been shown to have important roles in controlling cardiac re-
modeling and HF pathogenesis. The group led by Thomas Thum char-
acterized Chast, demonstrating its upregulation in murine CMs fol-
lowing TAC, but noted its concomitant expression in non-cardiac tissues
[91]. Consistent with these ﬁndings, the human ortholog of Chast was
found to be signiﬁcantly up-regulated in the hypertrophic hearts of
patients with aortic stenosis. Viral overexpression of Chast was suﬃ-
cient to trigger CM hypertrophy in both in vitro and in vivo systems.
Although targeting of lncRNA transcripts can be challenging due to
their generally low expression and subcellular localization (where they
are enriched in deﬁned chromatin compartments of the nucleus),
modiﬁed antisense oligonucleotides (ASOs) have shown eﬃcacy in ro-
bust and stable depletion of these species in vitro and in vivo. Indeed,
ASO-mediated silencing of Chast attenuated TAC-induced pathological
remodeling in adult mice in vivo. The lncRNA Chaer (cardiac-hyper-
trophy-associated epigenetic regulator) was discovered and character-
ized by Yibin Wang's group, who showed that it interacts with the
polycomb repressor complex 2 (PRC2) via a bi-tetra-loop motif within
the 5′-end of Chaer that is both necessary and suﬃcient for PRC2
binding [92]. Through this interaction, Chaer interferes with PRC2
genomic localization, thereby potentiating pathological gene transac-
tivation by reducing the repressive H3K27 histone methylation mark at
the promoters of these genes. Indeed, germline inactivation of Chaer
attenuated TAC-induced hypertrophy in mice in vivo. The translational
potential of these ﬁndings will require future studies to demonstrate
that silencing of Chaer at later stages of established HF is associated
with improved indices of cardiac remodeling in preclinical models.
The strategy used to discover the aforementioned lncRNAs all se-
lected for CM-enriched transcripts. Recently, there has been growing
interest in understanding the role of non-CM cell types in HF patho-
genesis with a particular focus on cardiac ﬁbroblasts, given their highly
plastic nature [70,93,94]. Upon cardiac stress, these cells undergo a
dramatic epigenetically-regulated shift in their cellular identity. While
ﬁbrotic responses may acutely serve to stabilize a focal area of myo-
cardial damage, clinical and experimental studies support the conten-
tion that excessive, diﬀuse, or chronic activation of these processes can
be deleterious to long-term cardiac function and patient survival. Re-
cent work from Jeﬀ Molkentin's group has implicated myoFBs (a sub-
population of stress-activated ﬁbroblasts that induce the marker gene
Periostin) as a cell type that can fuel the vicious cycle of adverse cardiac
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remodeling in HF [93,94]. As such, understanding the fundamental
mechanisms driving cardiac ﬁbroblast cell state transitions during stress
and uncovering novel approaches to target this process are of sig-
niﬁcant scientiﬁc and therapeutic interest. Thierry Pedrazzini's group
discovered Wisper (Wisp2 super-enhancer-associated RNA), a cardiac
ﬁbroblast-enriched lncRNA that regulates ﬁbrosis in HF [88]. They
identiﬁed Wisper using an existing database of annotated cardiac-en-
riched lncRNAs in HF samples [22], followed by iterative ﬁltering for
those that were transcribed from cardiac SEs, had human orthologues,
were induced in the setting of an MI, and were enriched in cardiac
ﬁbroblasts. In vitro loss-of-function studies demonstrated that Wisper
positively regulated myoFB gene expression and function, including
proliferation, migration, survival, and ECM deposition. ASO-mediated
depletion of Wisper in adult mice post-MI inhibited cardiac ﬁbrosis and
signiﬁcantly improved LV function. Mechanistically, Wisper was shown
to bind the RNA splicing factor TIA1 cytotoxic granule associated RNA
binding protein-like 1 (TIAR), preventing its nuclear translocation and
subsequent processing of pro-ﬁbrotic transcripts. Indeed, TIAR has been
previously shown to control the post-transcriptional processing of
PLOD2, a proﬁbrotic enzyme. Importantly, Wisper expression is not
detected in lung or kidney ﬁbroblasts at baseline and is not induced in
models of kidney ﬁbrosis, supporting the notion that Wisper may have
relative speciﬁcity for controlling cardiac ﬁbrosis. Furthermore, ex-
pression levels of the human Wisper ortholog correlate with the degree
of cardiac ﬁbrosis in heart tissue isolated from patients with aortic
stenosis, underscoring the translational relevance of these ﬁndings. We
note that theWisper locus contains both a SE DNA element as well as an
encoded enhancer-associated lncRNA, such that transcription at the
locus and/or the RNA itself may be involved in remodeling the local
chromatin topology and stabilizing chromatin loops between the SE and
its target promoters. Taken together, these ﬁndings demonstrate that
Wisper is a cardiac ﬁbroblast-enriched lncRNA that is conserved in
humans, promotes transcriptional activation of the myoFB cell state,
and functions as a potentially druggable target in human HF.
Ultimately, targeting lncRNAs for therapeutic purposes will require
a deep mechanistic understanding of how these species regulate gene
expression at the molecular level as well as determination of the spe-
ciﬁc cell types in which they function. While systemic delivery of nu-
cleic acid-based therapies to extrahepatic tissues remains in its early
days, this foundational knowledge will help improve the eﬃcacy of this
therapeutic strategy and increase our understanding of the toxicities
that may arise from manipulating these powerful regulators of cell
state.
5. Conclusions
The advent of novel sequencing technologies to dissect tran-
scriptomic and epigenomic landscapes has fundamentally advanced our
understanding of the gene control mechanisms that govern cell state.
The concept that aberrant cell state contributes to disease and can be
manipulated to exert therapeutic beneﬁt is well-established in cancer
biology, where novel therapies targeting these pathways are in active
clinical development. In contrast, our understanding of the epigenetic
mechanisms that contribute to HF pathogenesis is still in its infancy.
Here, we have provided examples of three classes of chromatin reg-
ulatory macromolecules (chromatin modifying enzymes such as G9a,
co-activator proteins such as BRD4, and chromatin regulatory lncRNAs)
that have been shown in proof-of-concept preclinical models to be
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Fig. 1. Stress-activated cardiac signaling cascades converge on deﬁned components of the chromatin regulatory apparatus. These events trigger activation of stress-
associated gene programs, Pol II pause release, cardiomegaly, ﬁbrosis, and ultimately heart failure (HF). Chromatin regulators in HF that can be pharmacologically
targeted with demonstration of translational potential include the histone methyltransferase G9a, members of the Bromo- and Extra- Terminal (BET) domain family,
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druggable epigenetic targets in HF (Fig. 1). In order to advance the
translational potential of these classes of molecules, future eﬀorts must
be directed at understanding the relevant cell types in which they are
acting and the mechanisms by which they function. Conditional genetic
approaches (where possible), single-cell based transcriptomic and epi-
genomic interrogations, and deﬁnition of the interaction partners for
these chromatin regulators (including not only proteins but also RNA
species) will be critical. Such studies may ultimately inform novel
therapeutic strategies that may be directed in a more cell-type restricted
manner, allowing for a greatly expanded therapeutic index of ap-
proaches that pharmacologically manipulate epigenetic signaling in
human HF.
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